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1. Supplemental Figures  
 
1.1. Supplemental Figure 1: Meta-analysis of studies testing the association of WMH with incident 
stroke (PVH replaced by DWMH for studies that do not have results for total WMH burden1-3)  
 
                                          Hazard Ratio
Wong 2002
Vermeer 2003
Kuller 2004
Bokura 2006
Debette 2009
Buyck 2009
   Total GP    3.1 (2.3-4.2)                
Yamauchi 2002
Gerdes 2006
Naka 2006
   Total HRP    6.1 (1.1-33.1)                
Overall      3.4 (2.4-4.8)
0.5 2 4 7 15 40
WMH and risk of stroke
 
 
DWMH: deep white matter hyperintensities; PVH: periventricular hyperintensities; WMH: white matter hyperintensities; Inverse 
variance meta-analysis; GP: general population; HRP: high risk population; all: overall meta-analysis; p for heterogeneity = 
0.84, 0.008, and 0.16 for GP, HRP and all respectively; I2 = 0%, 79.1%, and 32.5%, for GP, HRP and all respectively 
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1.2. Supplemental Figure 2: Meta-analysis of studies testing the association of WMH with incident 
dementia in patients with MCI  
 
 
 
MCI: Mild Cognitive Impairment; Inverse variance meta-analysis; p for heterogeneity = 0.26, I2 = 26.1% 
4 
 
1.3. Supplemental Figure 3: Meta-analysis of studies testing the association of WMH with incident 
dementia (PVH replaced by DWMH for studies that do not have results for total WMH burden 4)  
 
                                          Hazard Ratio
Kuller 2003          
Prins 2004          
Debette 2009          
   Total GP    1.8 (1.4-2.2)                
Geroldi 2006          
Firbank 2007          
Smith 2008          
Bombois 2008          
Kantarci 2009          
Jokinen 2009          
   Total HRP    1.4 (0.9-2.3)                
Overall      1.6 (1.2-2.2)
0.2 0.5 1 2 3 5 7 11
WMH and risk of dementia
 
 
DWMH: deep white matter hyperintensities; PVH: periventricular hyperintensities; WMH: white matter hyperintensities; Inverse 
variance meta-analysis; GP: general population; HRP: high risk population; all: overall meta-analysis; p for heterogeneity = 
0.38, 0.04, and 0.05 for GP, HRP and all respectively; I2 = 0%, 57.7%, and 48.0%, for GP, HRP and all respectively 
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1.4. Supplemental Figure 4: Meta-analysis of studies testing the association of WMH with incident 
AD  
 
 
 
AD: Alzheimer Disease; Inverse variance meta-analysis; p for heterogeneity = 0.74, I2 = 0% 
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1.5. Supplemental Figure 5: Meta-analysis of studies testing the association of WMH with mortality 
(PVH replaced by DWMH for studies that do not have results for total WMH burden 2 5)  
 
 
 
DWMH: deep white matter hyperintensities; PVH: periventricular hyperintensities; WMH: white matter hyperintensities; Inverse 
variance meta-analysis; GP: general population; HRP: high risk population; all: overall meta-analysis; p for heterogeneity = 
0.44, 0.06, and 0.03 for GP, HRP and all respectively; I2 = 0%, 60.4%, and 55.3%, for GP, HRP and all respectively 
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2. Supplemental Tables 
 
2.1. Supplemental Table 1: Association of WMH with incident stroke 
 
Author Mean Population N Fu (yrs) MRI characteristics WMH measure  Incident Results 
 General population 
Wong, 
2002 6 62.3 ARIC study 1684 4.7 1.5T; T1, T2, PD 
SQ (0-9), 
dichotomized (>3 
vs. <3) 
32 (25 IS, 5 
ICH, 2 mixed) 
HR=3.7(95%CI:1.7-7.8) †  for WMH >3 vs. <3    
HR=3.4(1.5-7.7) ‡  for WMH >3 vs. <3 
Vermeer, 
2003 1 72 
Rotterdam 
study 1077 4.2 1.5T; T1, T2, PD 
SQ (0-9) for PVH, 
quantitative for 
DWMH *, studied in 
tertiles and 
continuously 
57 (42 IS, 6 
ICH, 9 
unspecified) 
HR=4.7(2.0-11.2) ‡ for 3rd vs. 1st PVH tertile      
HR=1.36(1.20-1.54) ‡ per grade increase of 
PVH                                                                    
HR=3.6(1.4-9.2) ‡ for 3rd vs. 1st DWMH tertile 
Risk of stroke did not increase linearly with 
DWMH    
Kuller, 
2004 7  75.0 CHS study 3293 7 
1.5T (+0.35 in one of 
the 4 centres); T1, 
T2, PD 
SQ (0-9), 6 classes: 
0, 1, 2, 3, 4, >5 
(reference = 0) 
278 (225 IS) HR=3.0(1.9-4.7) 
§ for grade >5, for all stroke      
HR=2.9(1.7-4.8) for grade >5, for IS 
Bokura, 
2006 2 57.8 
Shimane 
study  2684 6.3 
0.15T, 0.2T, 1.5T;                            
T1, T2, ±PD, ±Flair 
SQ (0-4 for PVH, 0-
3 for DWMH), 
dichotomized (PVH: 
>3 vs. <3, DWMH: 
>2 vs. <2) 
102 (56 IS, 21 
ICH, 11 SAH, 
11 TIA, 3 
unspecified)  
OR=2.08(1.04-4.17) ‡ for PVH >3 vs. <3 
OR=2.73(1.32-5.63) ‡ for DWMH >2 vs. <2        
Buyck, 
2009 8 72.3 3C-study 1648 4.9 1.5T; T1, T2, PD 
quantitative 
(automated), 
studied in quartiles 
28 (22 IS, 5 
ICH, 1 
unspecified) 
HR=5.7(2.0–16.4) for quartile 4 vs. quartile 
1+2 of WMH ‡ 
HR=6.2(2.0-19.5) for quartile 4 vs. quartile 
1+2 of PVH ‡ 
HR=4.1(1.5-11.3) for quartile 4 vs. quartile 
1+2 of DWMH ‡ 
Debette, 
2009 9  62 
Framingham 
Offspring 
study 
2177 5.6 1.0T, 1.5T; T2 
quantitative 
(automated), 
studied 
continuously, also 
dichotomized a 
32 (26 IS, 5 
ICH,1 
unspecified) 
HR=1.33(0.93-1.90) for increasing WMH 
volume ‡   
HR=2.28(1.02-5.13) for extensive WMH ‡  
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Author Mean Population N Fu (yrs) MRI characteristics WMH measure  Incident strokes (n)  Results 
 High risk population 
Yamauchi
, 2002 10 66.0 
patients with 
lacunar stroke, 
headache or 
dizziness 
89 4.3 0.5T; T1, T2, PD 
SQ c studied continuously  
and dichotomous (severe 
vs. mild or absent) 
7 (5 IS, 2 ICH) HR=1.60(1.02-2.54) 
e 
                  
OR=20.5(3.6-118.0) f 
Smith, 
2004 11 76.3 
b
 
lobar ICH 
patients 82 
b
 2.7 b NA; Flair 
SQ (0-9) for PVH, 
quantitative for DWMH, 
dichotomized  (middle or 
high vs. low tertile)  
NA (recurrent ICH) HR=9.0(1.2-67.2) for PVH           NS for DWMH (no HR) 
Appelros, 
2005 12 66.4 
lacunar stroke 
patients 81 5.0 1.0T; T2 
SQ d, studied 
continuously 
24 (21 IS, 2 ICH, 1 
unspecified) HR=1.7(1.2-2.7) 
g
  
Fu, 2005 
13
 
68.3 stroke patients 228 1.9 1.5T; T1, T2, Flair, DWI 
SQ (0-3); studied 
continuously 29 (23 IS, 6 ICH) HR=4.18(2.04-8.56) 
‡
 
Gerdes, 
2006 3 62 
patients with 
recent IS, 
myocardial 
infarction or 
peripheral artery 
disease 
230 3.5 1.5T; T1, T2, PD 
SQ (PVH+/-, DWMH+/- 
and for total WMH: none, 
<50%, >50% of total white 
matter) 
21 (IS) 
HR=4.4(1.8-11.0)  for PVH+/-  
HR=3.2(1.3-8.4) h for PVH+/-       
HR=1.5 (0.6–3.8) for 
DWMH+/-                     
Naka, 
2006 14 67.2 stroke patients  266 1.5 1T; T2, T2* 
SQ (0-3); dichotomized 
(>2 vs. <2)  26 (16 IS, 10 ICH) 
HR=10.7(2.6-43.7) for IS i            
HR=0.016(0.001-0.258) for 
ICH i                         
 
CVD: cerebrovascular disease; DWMH: deep white matter hyperintensities; Fu: follow-up; HR: hazard ratio; ICH: intracerebral hemorrhage; IS: ischemic stroke; NA: not available; NS: non significant; OR: odds ratio; PD: 
proton density; PVH: periventricular hyperintensities; SAH: subarachnoid hemorrhage; SQ: semi-quantitative; TIA: transient ischemic attack; WMH: white matter hyperintensities; * approximation (based on number and 
size of lesions); † adjusted for age, sex; ‡ adjusted for age, sex, vascular risk factors; § adjusted for clinic, age, sex, vascular risk factors; a extensive WMH: > age-group specific mean[logWMH]+1SD; b with MRI (182 
patients overall, 100 had computed tomography only), mean follow-up and age are for overall group; c van Swieten15; d Wahlund scale16; e adjusted for age, sex, vascular risk factors, multiple lacunar infarcts; f computed 
by authors of meta-analysis from published raw numbers, for severe vs. mild or no WMH; g adjusted for age, ischemic heart disease, impairment score, MMSE, basal ganglia score; h adjusted for age, hypertension, type 
of atherosclerotic disease at entry; i adjusted for age, sex, vascular risk factors, stroke type, days from stroke onset, microbleeds 
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2.2. Supplemental Table 2: Association of WMH with incident dementia 
 
Author Mean 
age  Population N 
Fu 
(yrs) 
MRI 
characteristics WMH measure  
Incident 
dementia, n  
Dementia 
type Results 
 General population 
All dem HR=1.7(95%CI:1.36-2.10) for WMH>3 †     
AD HR=1.5(1.17-1.99) for WMH>3 †     
Kuller, 
2003 17 >65 CHS 3375 NA 
1.5T; T1, T2, 
PD 
SQ (0-9), 
dichotomized 
(>3 vs. <3) 
480 (criteria not 
specified): 52 
VaD, 76 MD, 
330 AD VaD/MD HR=2.1(1.36-3.11) for WMH>3 †    
All dem 
HR=1.67(1.25-2.24) ‡  for PVH 
(NS for DWMH) 
HR=2.2(1.0-4.8) for DWMH >6 a      
HR=4.4(1.9-5.0) for PVH >6 a           Prins, 
2004 4 72.2 
Rotterdam 
study 1077 5.2 
1.5T; T1, T2, 
PD   
SQ (0-9) for 
PVH, 
quantitative for 
DWMH *, 
continuous (per 
SD increment) 
and 
dichotomized 
45 (DSM-IIIR): 
34 AD, 6 VaD, 
5 other types 
AD HR=1.41(1.01-1.98) 
‡
 for PVH 
(NS for DWMH) 
AD 
OR=0.78(NS) for increasing PVH     
OR=1.07, 1.02(NS) for DWMH 
right and left               Meguro, 
2007 18 >65 
Osaki–Tajiri 
project 257 5 1.5T; T1, T2 
SQ: PVH (4 
grades), DWMH 
(4 grades), 
continuous 
27 (DSM-IV 
and CDR1+): 
17 AD 
(NINCDS-
ADRDA), 5 
VaD (NINDS-
AIREN) 
VaD 
OR=4.14(p<0.005) for PVH              
OR=4.04, 3.27(p<0.05) for DWVH 
right and left                              
Debette, 
2009 9 62 
Framingham 
Offspring 
study 
2013 5.9 1.0T, 1.5T; T2 
quantitative 
(automated), 
continuous and 
dichotomized b 
11 (DSM-IV): 7 
AD, 3 VaD, 1 
other 
 All dem 
HR=2.22(1.32-3.72) § for 
increasing WMH HR=3.97 (1.10-
14.30) § for extensive WMH 
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Author Mean 
age  Population N 
Fu 
(yrs) 
MRI 
characteristics WMH measure  Incident dementia, n  
Dementia 
type Results 
 High risk population 
Steffens, 
2000 19  >60 depression 182 1 to 5 1.5T; T2 
quantitative 
(automated) 
26 (criteria not 
specified), type 
unspecified 
All dem No association 
Korf, 
2004 20 62.9 MCI  75 2.8 1.5T; T2, PD SQ 
c
, continuous 37 (DSM-IV): 34 AD, 3 VaD All dem HR=1.01(0.94-1.08)                                
De Carli, 
2004 21 72.8 MCI  52 3.1 1.5T; T1, T2, PD 
quantitative 
(automated), 
continuous 
17 (CDR>1.0): 10 AD, 
4 MD, 2 VaD, 1 other  All dem HR=0.73(0.35-1.54) 
h
 
Geroldi, 
2006 22  70.0 MCI 52 1.3 
1.0T; gradient 
echo 
SQ c, 
dichotomized e 
11 (DSM-IV): 7 AD, 1 
VaD, 1 DLB All dem OR=2.9(0.7-11.4) 
Steffens, 
2007 23 69.2 depression 161 5.4 1.5T; T2  
quantitative 
(automated) 
20 (DSM-IV): 10 AD, 3 
VaD, 7 undetermined All dem No association 
i
 
Firbank, 
2007 24 80.1 stroke 79 2 1.5T; T1, Flair 
quantitative 
(automated), 
continuous and 
dichotomized (> 
vs. < 1/4 of white 
matter) 
14 (DSM-IV): type not 
available All dem 
OR=1.0(0.2-4.1) j 
 
Smith, 
2008 25  72.3 MCI 156 6.4 1.5T; T2, PD 
quantitative 
(automated), 
dichotomized f 
54 (DSM-IV): 45 AD All dem HR=1.26(0.61-2.59) 
Tapiola, 
2008 26 72.7 MCI 60 2.8 
1.5T; T2, Flair, 
PD SQ 
c
, continuous 13 (DSM-IV): 9 AD, 3 VaD, 1 MD  All dem HR=1.01(0.89-1.14) 
All dem HR=1.01(0.97-1.05) per unit WMH k 
HR=1.32(0.77-2.24) for WMH >6 k,l       
VaD/MD HR=1.14(1.06-1.24) per unit WMH k      
HR=10.00(1.55-64.39) for WMH >6 k     
HR=2.71(1.60-4.58) per unit PVH k       
Bombois
, 2008 27 68.1 MCI 170 3.8 1.5T; T1, T2, PD 
SQ g, continuous, 
and also 
dichotomized for 
total WMH (> vs. 
<median)  
67 (DSM-IV): 29 AD 
(NINCDS-ADRDA), 19 
DLB, 8 MD, 7 VaD 
(NINDS-AIREN) AD HR=1.02(0.96-1.09) per unit WMH k,l     
HR=1.67(0.73-3.81) for WMH >6 k,l       
Van 
Straaten
, 2008 28 
72.4 amnestic MCI 152 3 NA; T1, T2, PD SQ 
g
, continuous  55 (NINCDS-ADRDA): 55 AD AD 
HR=1.03(0.99–1.06) m  for total WMH    
HR=1.02(0.97–1.08) m  for DWMH         
HR=1.59(1.24–2.05) m  for PVH             
 
11 
 
Author Mean 
age  Population N 
Fu 
(yrs) 
MRI 
characteristics WMH measure  Incident dementia, n  
Dementia 
type Results 
 High risk population 
Kantarci, 
2009 29 77 MCI 151 2.1 1.5T; T1, Flair 
quantitative 
(visual scale), 
dichotomized 
(>mean+1SD) 
75 (DSM-III): 57 AD, 
15 DLB, 3 FTLD All dem HR=0.75(0.42-1.35) 
n
 
Jokinen, 
2009 30 73.5 
with WMH 
and minor 
neurologica
l problems  
639 3 0.5T, 1.5T; T1, T2, Flair 
SQ d, 
dichotomized into 
presence (or 
absence of SIVD) 
91 (DSM-IV) All dem OR=3.01(1.64-5.55) o 
Staeken
borg, 
2009 31 
69.9 MCI patients 152 2.0 
1.0T; T1, Flair, 
T2* 
SQ g, 
dichotomized into 
< vs. >6 for WMH, 
< vs. >3 for PVH, 
< vs. >4 for 
DWMH 
72: 56 AD (NINCDS-
ADRDA), 16 non-AD 
(7 VaD, 5 FTLD, 2 
DLB, 1 PD, 1 alcohol 
dementia) 
AD 
 
 
Non-AD 
HR= 1.2(0.7-2.2) ‡  for WMH >6 
HR= 1.3(0.8-2.3) ‡  for DWMH >4 
HR= 1.1(0.7-2.0) ‡  for PVH >3 
HR= 5.8(1.2-26.6) ‡ for WMH >6 
HR= 5.7(1.2-26.7) ‡ for DWMH >4 
HR= 6.5(1.4-29.8) ‡ for PVH >3 
 
AD: Alzheimer’s disease; All dem: all types of dementia; CDR: Clinical Dementia Rating scale 32; DLB: dementia with Lewy bodies; DSM-III: Diagnostic and Statistical Manual of Mental Disorders, Revised 
Third Edition 33; DSM-IV: Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition 34; DWMH: deep white matter hyperintensities; FTLD; frontotemporal lobe dementia; Fu: follow-up; HR: hazard 
ratio; MCI: mild cognitive impairment; MD: mixed dementia; NA: not available; NINCDS-ADRDA: criteria for AD from the National Institute of Neurological and Communicative Disorders and Stroke and the 
Alzheimer's Disease and Related Disorders Association 35; NINDS-AIREN: National Institute of Neurological Disorders and Stroke and the Association Internationale pour la Recherche et l’Enseignement en 
Neurosciences 36; NS: non significant; OR: odds ratio; PD: proton density; PVH: periventricular hyperintensities; SIVD: subcortical ischemic vascular disease, defined by either severe WMH (Fazekas scale37) 
plus >1 lacune or moderate WMH37 plus >5 lacunes; SQ: semi-quantitative; VaD: vascular dementia; WMH: white matter hyperintensities; * approximation (based on number and size of lesions); † adjusted for 
age, sex, race, education, baseline cognition, ApoEε4, ventricular grade, infarcts on MRI, vascular risk factors, stroke, subclinical disease; ‡ adjusted for age, sex; § adjusted for age, sex, vascular risk factors; a 
numbers computed from graph; b extensive WMHV: >age-group specific mean[logWMH]+1SD; c Wahlund scale16; d grade 1 to 3 from Fazekas scale37; e extensive WMH if total score>6 or any regional 
score>2; f extensive WMH if log-transformed >mean+1SD; g Scheltens scale38; h adjusted for age, sex, education, cortical gray matter, hippocampal volume, lacunes; i adjusted for age, sex, baseline cognition, 
education; j OR computed by authors of meta-analysis from the raw data; k adjusted for age, sex, education, medial temporal lobe atrophy, vascular risk factors, baseline cognition; l unpublished data; m 
adjusted for age, education; n adjusted for age, sex, education; o adjusted for age, sex, education, medial temporal lobe atrophy 
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2.3. Supplemental Table 3: Association of WMH with cognitive decline 
 
Author Mean 
age 
Population N Fu 
(yrs) 
MRI 
characteristics 
WMH measure  Cognitive decline measure  Results 
       
 
 General population 
Kuller, 1998 
39
 
>65 CHS 3469 3 1.5T; T1, T2, 
PD   
SQ (0-9), dichotomized 
(>3 vs. <3) 
global (3MSE) no association with loss of >5 points on 
3MSE;                         OR=1.4(95%CI:1.0-
1.9) for 3MSE<80 at the end of fu  
Schmidt, 
2005 40 
60.2 ASPS 329 6 1.5T; T1, T2, 
PD  
quantitative 
(automated), continuous 
domain-specific (composite z-
score for each cognitive 
domain [memory, 
conceptualization, 
visuopractical skills, 
attention/speed]) 
no association of baseline WMH volume with 
decline in composite z-score † 
Prins, 2005 
41
 
71 Rotterdam 
study 
832 5.2 1.5T; T1, T2, 
PD   
SQ (0-9) for PVH, 
quantitative for DWMH, 
studied in quintiles  
global (MMSE and cognitive 
index) and domain-specific 
(Stroop, Letter Digit 
Substitution Task, Verbal 
Fluency test, 15-word verbal 
learning test) 
per SD increase in PVH, the annual MMSE 
decline increased by 0.035 points (0.003-
0.066); decline in Stroop naming and Letter 
Digit Substitution Test associated with PVH 
(p=0.04, <0.01); no association with DWMH 
Smith, 2008 
25
 
71.2 cognitively 
intact 
67 5.1 1.5T; T2, PD quantitative 
(automated), 
dichotomized * 
global (conversion to MCI 
[n=26]) 
HR=2.59(1.07-6.25)                                           
HR=3.30(1.33-8.17) ‡ for progression to MCI 
in subjects with extensive WMH 
Debette, 
2009 9 
62 Framingham 
Offspring 
study  
1344 6.2 1.0T, 1.5T; T2 quantitative 
(automated), 
continuous, also 
dichotomized c 
global (conversion to MCI 
[n=93/1344], and to amnestic 
MCI [n=93/1134]) 
incident all MCI: HR=1.06(0.83-1.36) § for 
increasing WMH volume 
                           HR=1.26(0.67-2.39) § for 
extensive WMH  
incident amnestic MCI: HR=1.24(0.98-1.57) § 
for increasing WMH volume a 
                                      HR=1.67(0.96-2.93) § 
for extensive WMH a 
Silbert, 
2009 42 
62 cognitively 
intact 
98 9.5 1.5T; T1, T2, 
PD 
quantitative 
(automated), continuous 
global (conversion to 
permanent cognitive 
impairment [n=53/98]) 
HR=1.04(1.00-1.07) b for increasing total 
WMH  
HR=1.06(1.01-1.10) b for increasing PVH 
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Author Mean 
age 
Population N Fu 
(yrs) 
MRI 
characteristics 
WMH measure  Cognitive decline measure  Results 
       
 
 High risk population 
Mungas, 
2002 43 
73.0 memory 
clinic: 68 
CDR=0; 38 
CDR=0.5; 14 
CDR>1 
120 3.0 1.5T; T1, T2, 
PD 
quantitative (automated), 
continuous 
global (global cognitive change 
derived from word list learning 
test, digit span, letter fluency, 
animal category fluency) 
WMH was not related to global cognitive 
change (p=0.36) g  
Smith, 2004 
11
 
76.3 lobar ICH 82 c 2.7 * NA; Flair SQ (0-9) for PVH, 
quantitative for DWMH, 
dichotomized (middle or 
high vs. low tertile) 
global (incident cognitive 
impairment [deficits in memory or 
other cognitive areas interfering 
with tasks of daily living]) 
no association of PVH (p=0.85) or 
DMWH (p=0.44) with incident cognitive 
impairment 
Appelros, 
2005 12 
66.4 lacunar 
stroke 
81 5.0 1.0T; T2 SQ d, studied continuously global (MMSE) correlation coefficient =0.21 (NS) for 
decline in MMSE, =0.41 (p<0.01) for 
MMSE at 5 yrs 
Van der 
Flier, 2005 
44
 
73 memory 
complaints, 
MCI or 
normal 
59 1.8 1.5T; T1, T2, 
PD, Flair 
quantitative (automated), 
continuous 
global (CAMCOG) WMH volume was significantly 
associated with annual change in 
CAMCOG (β=−0.1; p<0.05) h  
Mungas, 
2005 45 
73.8 memory 
clinic: 58 
CDR=0; 34  
CDR=0.5; 11 
CDR>1 
103 4.8 1.5T; T1, T2, 
PD 
quantitative (automated), 
continuous 
domain-specific (composite 
memory measure derived from 
delayed, cued recall and word 
list learning task; composite 
executive function scale using 
letter fluency, digit span 
backward, visual span backward, 
initiation-perseveration scale) 
baseline WMHV was related to change 
in executive functions (p=0.02), f  NS 
after additional adjustments i 
Van den 
Heuvel, 
2006 46 
75 vascular risk 
+ MMSE>24  
554 3 1.5T; T2, PD, 
Flair 
quantitative (automated), 
studied in 3 strata (low, 
intermediate, high)  
domain-specific (picture word 
learning test; letter digit coding 
test; abbreviated Stroop test) 
higher PVH at baseline associated with 
more time to complete the Stroop test 
(p=0.008) j, no association with DWMH 
Debette, 
2007 47 
68.1 MCI 170 3.8 1.5T; T1, T2, 
PD 
SQ e, dichotomous 
(>vs<median) and in 
tertiles 
global (MMSE and DRS) and 
domain-specific (DRS subitems) 
decliners more often had PVH or DWMH 
> median; mean annual decline in 
MMSE and DRS-initiation higher with 
increasing PVH tertiles; decline in MMSE 
associated with PVH > median k 
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Author Mean 
age 
Population N Fu 
(yrs) 
MRI 
characteristics 
WMH measure  Cognitive decline measure  Results 
       
 
 High risk population 
Firbank, 
2007 24 
80.1 Stroke 79 2 1.5T; T1, Flair quantitative (automated), 
continuous 
global (CAMCOG) no association of CAMCOG score at 2 
years with WMH at baseline (β=−0.08; 
p=0.5) 
Jokinen, 
2009 30 
73.5 with WMH 
and minor 
neurological 
problems 
639 3 0.5T, 1.5T; T1, 
T2, Flair 
SQ f, dichotomized into 
presence (or absence of 
SIVD) 
global (MMSE); domain-specific 
(immediate and delayed word 
recall, Stroop, trail making test A 
and B-A, verbal fluency, symbol 
digit modalities and digit 
cancellation test, digit span 
backward)  
participants with SIVD had a steeper 
decline for MMSE (p=0.03), verbal 
fluency (p=0.007), Stroop I (p=0.007), 
Stroop II (p=0.005), TMT A (p<0.001)  
Dufouil, 
2009 48 
60.5 stroke or TIA, 
in 
PROGRESS 
trial 
226 4 1.0T, 1.5T; 
T2/PD 
SQ e, categorized in 4 
grades (none, mild, 
moderate, severe) 
global (dementia [DSM-IV] or 
severe cognitive decline (decline 
in MMSE of >= 3 points) 
RR=7.6 (1.9–31.2) for severe vs. none l 
 
3MSE: Modified Mini-Mental State Examination 49; CAMCOG: Cambridge Assessment Mental Disorders in the Elderly, section B 50; CDR: Clinical Dementia Rating 
scale 32 ; DRS: Dementia Rating Scale 51; DWMH: deep white matter hyperintensities; HR: Hazard ratio; MCI: mild cognitive impairment; MMSE: mini-mental state 
examination 52; OR: odds ratio; PVH: periventricular hyperintensities; RR: relative risk; SIVD: subcortical ischemic vascular disease, defined by either severe WMH 
(Fazekas scale37) plus >1 lacune or moderate WMH37 plus >5 lacunes; SQ: semi-quantitative; * extensive if log-transformed >1SD from study mean; † no numbers; ‡ 
adjusted for ApoEε4, age, sex, education, smoking, CDR sum of boxes; § adjusted for age, sex, education, vascular risk factors, duration of follow-up ; a significant in 
participants aged >60 years; b adjusted for age, hypertension, MMSE, ApoEε4, intracranial and hippocampal volume; c with MRI (182 patients overall, 100 had 
computed tomography only), mean follow-up and mean age is for overall group; d Wahlund scale16; e Scheltens scale38; f grade 1 to 3 from Fazekas scale37; g adjusted 
for age, education, sex; h adjusted for age, sex and duration of follow up; i additionally adjusted for hippocampal volume, cortical gray matter volume, presence of 
lacunes; j adjusted for sex, age, education, treatment group, and test version when applicable; k adjusted for age, sex, education, vascular risk factors, medial 
temporal lobe atrophy, MCI subtype, +/- baseline cognitive performances; l adjusted for age, sex, education, hypertension, physical impairment, baseline MMSE and 
treatment allocation 
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2.4. Supplemental Table 4: Association of WMH progression with cognitive decline 
 
Author Mean Population N Fu MRI WMH progression Cognitive decline measure  Results 
   
    
 
 General population 
Longstreth, 
2005 53  
74.1 CHS 1919 5 1.5T; T1, T2, 
PD   
SQ, worsening WMH 
grade (0-9), defined 
by 3 levels (increase 
of 0, 1, >2 points)   
global (3MSE) and domain-specific 
(digit symbol substitution test) 
3MSE and digit symbol substitution 
test scores deteriorated significantly 
more with increasing WMH 
progression ‡   
Schmidt, 
2005 40 
60.2 ASPS 329 6 1.5T; T1, T2, 
PD  
quantitative 
(automated), 
continuous 
domain-specific (composite z-score 
each domain: memory, 
conceptualization, visuopractical 
skills, attention/speed)  
progression of WMH significantly 
associated with declining 
performance in memory, 
conceptualization and visuopractical 
skills a 
Kramer, 
2007 54  
73.9 healthy 
elderly 
subjects 
50 3.8 1.5T; T1, T2, 
PD 
quantitative 
(automated), 
continuous 
domain-specific (composite memory 
measure derived from delayed and 
cued recall and word list learning 
task; composite executive function 
score using letter fluency, digit span 
backward, visual span backward, and 
an initiation-perseveration scale) 
delta-WMH volume significantly 
associated with composite executive 
function score at the end of follow-up 
(ß=0.261, p=0.022) c, no significant 
association of delta-WMH volume 
with composite memory measure at 
the end of follow-up  
Van Dijk, 
2008 55 
71 Rotterdam 668 3.4 1.5T; T1, T2, 
PD 
SQ, studied in 3 
classes (no 
progression, minor 
progression, marked 
progression)                            
global (MMSE, composite score for 
global cognitive function) and 
domain-specific (z-scores for 
memory performance and 
psychomotor speed) 
increased mean change in MMSE 
(p=0.02) for marked PVH 
progression, in psychomotor speed 
for any or marked PVH progression 
(p<0.01), in global cognitive function 
for any (p<0.01) and marked 
(p=0.02) PVH progression; no 
association with DWMH change 
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Author Mean Population N Fu MRI WMH progression Cognitive decline measure  Results 
       
 
 High risk population 
Van den 
Heuvel, 
2006 46 
75 vascular 
risk + 
MMSE>24  
554 3 1.5T; T2, PD, 
Flair 
quantitative 
(automated), studied 
in 3 strata (low, 
intermediate, high) 
domain-specific (memory: picture 
word learning test; executive 
functioning and attention: letter digit 
coding test and abbreviated Stroop 
color word test) 
larger progression in PVH volume 
associated with more time to 
complete the Stroop test (p=0.02) b 
Mungas, 
2005 45 
73.8 memory 
clinic: 58 
CDR=0, 34 
CDR=0.5, 
11 CDR>1 
103 4.8 1.5T; T1, T2, 
PD 
quantitative 
(automated), 
continuous 
domain-specific (composite memory 
measure derived from delayed and 
cued recall and word list learning 
task; composite executive function 
scale using letter fluency, digit span 
backward, visual span backward, and 
an initiation-perseveration scale) 
no association with WMH change § 
 
3MSE: Modified Mini-Mental State Examination 49; CDR: Clinical Dementia Rating scale 32; DWMH: deep white matter hyperintensities; MMSE: mini-mental state examination 52; PVH: periventricular 
hyperintensities; SQ: semi-quantitative; TIA: transient ischemic attack; WMH: white matter hyperintensities; * no neuropsychiatric disease at baseline; ‡ adjusted for age, sex, education, performance and WMH 
grade at baseline, occurrence of TIA or stroke (unchanged when adding worsening atrophy and presence of infarcts to model); § adjusted for age, education, sex; a adjusted for sex, age, education, major 
vascular risk factors (non significant after adjusting for brain volume change); b adjusted for sex, age, education, treatment group, and test version when applicable (non significant after adjusting for incident 
brain infarction; c adjusted for baseline executive function, change in hippocampal volume, cortical grey matter, and lacunes 
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2.5. Supplemental Table 5: Association of WMH with mortality 
 
Author Mean 
age 
Population N Fu (yrs) MRI 
characteristics 
WMH measure  Incident 
deaths (n)  
Results 
 
        General population 
Bokura, 
2006 2 
57.8 Shimane study  2684 6.3 0.15T, 0.2T, 
1.5T; T1, T2, 
±PD, ±Flair 
SQ (0-4 for PVH, 0-3 for 
DWMH), dichotomized 
(PVH: >3 vs. <3) and 3 
classes (DWMH: 0, 1, 
>1) 
93 OR=4.01(95%CI:1.91-8.45) †  for PVH >3 vs. 
<3                                                                    
OR=0.63(0.32–1.25) †  for 1 vs. 0 DWMH               
OR=1.06(0.45–2.53) †  for >1 vs. 0 DWMH 
Kuller, 
2007 56 
74.8 CHS 3245 10 to 12 1.5T; T1, T2, PD SQ (0-9); 5 classes: 0-1, 
2, 3, 4, >5 (reference = 
0-1) 
1056 HR=2.22(1.75-2.82)  for grade > 5 vs. 0-1            
(p for trend <0.0001 across grades) ‡ 
Ikram, 
2007 57 
73.4 Rotterdam 
study 
490 8.4  1.5T; T1, T2, 
PD, HASTE 
quantitative (automated) 
, continuous and in 
quartiles 
191 HR=1.38(1.16-1.65) per SD increase in WMH 
volume HR=2.05(1.32–3.20) for 4th vs. 1st 
quartile §,a 
Debette, 
2009 9 
62 Framingham 
Offspring 
study 
2208 5.2 1.0T, 1.5T; T2 quantitative (automated) 
, continuous and 
dichotomized * 
97 HR=1.38(1.13-1.69) † for increasing WMH 
volume 
HR=2.27(1.41-3.65) † for extensive WMH a 
         High risk population 
Yamauchi, 
2002 10 
66.0 lacunar stroke, 
headache or 
dizziness 
89 4.3 0.5T; T1, T2, PD SQ b, dichotomized 
(presence vs. absence) 
4 0R=0.26(0.03-2.59) e 
Levy, 2003 
5
                            
70 depression 259 5.5 1.5T; T1,T2 SQ: PVH (0-3), DWMH 
(0-3), SGMH (0-3), 
studied as binary 
variable (2-3 vs. 0-1) 
30 HR=3.43(1.29-9.08) for DWMH f                    
OR=2.36(1.07-5.21) for PVH j 
association with PVH non significant in Cox 
regression including DWMH 
Appelros, 
2005 12 
66.4 lacunar stroke 81 5.0 1.0T; T2 SQ d, studied 
continuously 
15 HR=1.6(1.2-2.2) g                 
Fu, 2005 13 68.3 stroke 228 1.9 1.5T; T1, T2, 
Flair, DWI 
SQ (0-3), studied 
continuously 
25 HR=2.02(1.03-3.96) † 
Kerber, 
2006 58 
>75 mild imbalance 108 11.8 1.5T; T1, T2 SQ (0-2), grade 0 = 
reference 
62 HR=1.98(1.06-3.7)  
HR=2.31(1.21-4.40) h  for grade 2 vs. 0 
Oksala, 
2009 59 
70.8 stroke 396 7.5 1.0T; T1, T2, PD  SQ d , dichotomized: 
severe vs. mild to 
moderate 
277 HR=1.31(1.00-1.71) i,a 
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DWMH: deep white matter hyperintensities; DWI: diffusion-weighted imaging; Fu: follow-up; HASTE: 3D half-Fourier acquisition single-shot turbo spin echo sequence; HR: hazard ratio; OR: odds ratio; PD: 
proton density; PVH: periventricular hyperintensities; SGMH: subcortical grey matter hyperintensities; SQ: semi-quantitative; WMH: white matter hyperintensities; * extensive WMHV: > age-group specific 
mean[logWMH]+1SD; † adjusted for age, sex, vascular risk factors; ‡ adjusted for age, sex and race (still significant when adjusting for vascular risk factors, incident dementia, infarct on MRI); § adjusted for 
age and sex (unchanged after adjustment for vascular risk factors and after censoring for incident dementia or stroke); a the association was stronger with vascular death; b Wahlund scale16; c none to mild, 
moderate, severe (modified Fazekas scale37); d van Swieten15; e OR computed by authors of meta-analysis from published raw numbers; f adjusted for age, sex, race, measure of comorbidity, MMSE; g non 
significant in multivariable model; h age- and sex-matched and adjusted for vascular risk factors and coronary heart disease; i stepwise model including age, sex, vascular risk factors, vascular disease and 
poor modified Rankin score; j OR computed by authors of meta-analysis using raw numbers   
 
 
19 
 
3. Supplemental Methods 
 
3.1. Supplemental Methods 1: Data sources 
 
References for this review were identified through searches of PubMed from 1966, to November 23rd 2009, 
using pre-defined search terms ( "white matter" or "periventricular" or "subcortical" or ("Leukoaraiosis"[Mesh] 
or "Leukoaraiosis/pathology"[Mesh])) and ("Dementia" or "Alzheimer disease" or "Vascular dementia” or 
"Stroke" or "Brain Infarction" or "Cerebral Hemorrhage" or "Death" or "Mortality" or “cognitive” or 
("Stroke"[Mesh] or "Stroke/epidemiology"[Mesh]) or ("Dementia"[Mesh] or "Dementia/epidemiology"[Mesh]) or 
"Death"[Mesh] or "Mortality"[Mesh]) and ("Magnetic Resonance Imaging"[Mesh]) and ("Risk Factors"[Mesh] or 
"Longitudinal Studies"[Mesh] or "Cohort Studies"[Mesh]), restricted to research in humans. 
Only papers published in peer-reviewed journals were selected. 
 
3.2. Supplemental Methods 2: Study selection 
 
We excluded studies on white matter lesions occurring in inflammatory or neurodegenerative conditions such 
as multiple sclerosis, auto-immune disorders such as lupus or Sneddon syndrome, or in monogenic 
neurodegenerative diseases such as Huntington’s disease, neurofibromatosis, and leukodystrophies, as well 
as studies on WMH in monogenic cerebrovascular disease such as CADASIL, Fabry disease, and sickle cell 
disease. We also did not include studies where the outcome was MRI-defined (including silent) brain infarcts 
instead of clinical stroke, or subjective cognitive decline instead of objective cognitive decline evaluated by 
standardized neuropsychological tests, as well as studies on the association of WMH with cognitive decline in 
already demented individuals.  
We reviewed abstracts of identified articles in all languages. For those potentially meeting the inclusion criteria 
the full paper was reviewed.  
 
3.3. Supplemental Methods 3: Statistical analyses 
 
For studies that measured deep WMH (DWMH) and periventricular hyperintensities (PVH) separately, and did 
not provide a global risk estimate for WMH, the results for PVH were used for the meta-analysis. Indeed, it 
has been shown that although PVH and DWMH volumes are both very strongly associated with global WMH 
burden, there is a steeper slope of change in PVH volume with increasing total WMH volume.60 
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